Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Design Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
DSGN
Nasdaq
2836
www.designtx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Design Therapeutics, Inc.
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
- Jun 4th, 2025 5:00 am
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
- May 28th, 2025 6:00 am
3 Penny Stocks With Market Caps As Low As $70M To Watch
- May 22nd, 2025 12:05 pm
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
- May 13th, 2025 6:00 am
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
- May 7th, 2025 2:01 pm
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops
- May 2nd, 2025 5:58 am
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
- May 1st, 2025 6:00 am
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
- Apr 21st, 2025 2:01 pm
April 2025's Promising Penny Stocks
- Apr 18th, 2025 6:05 am
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
- Apr 17th, 2025 6:00 am
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
- Apr 17th, 2025 5:00 am
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
- Mar 12th, 2025 10:00 am
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
- Mar 10th, 2025 5:07 am
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
- Mar 3rd, 2025 6:00 am
US Penny Stocks To Watch In February 2025
- Feb 19th, 2025 5:10 pm
3 Promising US Penny Stocks With Market Caps Under $900M
- Jan 21st, 2025 5:07 pm
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
- Nov 13th, 2024 6:00 am
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
- Nov 7th, 2024 2:01 pm
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
- Nov 6th, 2024 5:27 am
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock
- Sep 26th, 2024 5:55 am
Scroll